ADVERTISEMENT
site_logo
  • Campus
  • Happening
  • Opinion
  • People
  • News
  • #BeInspired
  • Careers
  • 40 under 40
  • Exams
  • What The FAQ
  • Videos
    • Straight Up
    • Odisha Literary Festival 2020
    • Campus Convo
    • Careers After Corona
    • Express Expressions
    • Q&A With Prabhu Chawla
    • ThinkEdu Awards 2020
  • Web Stories
  • edex_worksEDEXWORKS
ADVERTISEMENT
COVID-19

Published: 07th May 2021     

Is Sotrovimab the new treatment for mild COVID cases? European Medicines Agency seeks authorisation

Sotrovimab is a monoclonal antibody, a lab-produced antibody that is intended to stimulate the immune system by reducing the ability of the coronavirus's spike protein to enter the body's cells

Edex Live
Edex Live
f_icon t_icon i_icon l_icon koo_icon whatsapp_icon email_icon Google News

Share Via Email

coronavirus-drugs

Image for representational purpose only

The European Medicines Agency says it has begun an accelerated authorisation process for an experimental Coronavirus treatment made by GlaxoSmithKline and Vir BioTechnology.

In a statement on Friday, the EU drug regulator said it had started a rolling review of Sotrovimab, based on early results from an ongoing study into whether the treatment can prevent hospitalisation or death in people who don't yet have severe COVID-19.

But EMA said it had not yet received the complete data and cautioned that “it is too early to draw any conclusions about the benefit-risk balance of the medication.”

Although the EMA has given the green light to four vaccines, there are few licensed treatments for the coronavirus, especially any that might prevent people with mild COVID-19 from progressing to severe disease.

Sotrovimab is a monoclonal antibody, a lab-produced antibody that is intended to stimulate the immune system by reducing the ability of the coronavirus's spike protein to enter the body's cells.

An emergency use authorisation for Sotrovimab has also been submitted to regulators in the US and Canada.

telegram
TAGS
COVID-19

O
P
E
N

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
telegram
ADVERTISEMENT
Write to us!

If you have campus news, views, works of art, photos or just want to reach out to us, just drop us a line.

newsletter_icon
Mailbox
edexlive@gmail.com
fb_icon
Facebook
twitter_icon
Twitter
insta_icon
Instagram
ADVERTISEMENT
Facebook
ADVERTISEMENT
Tweets by Xpress_edex
ADVERTISEMENT
ADVERTISEMENT

FOLLOW US

The New Indian Express | The Morning Standard | Dinamani | Kannada Prabha | Samakalika Malayalam | Cinema Express | Indulgexpress | Events Xpress

Contact Us | About Us | Privacy Policy | Terms of Use | Advertise With Us

Home | Live Now | Live Story | Campus Trip | Coach Calling | Live Take

Copyright - edexlive.com 2023. All rights reserved. Website Designed, Developed & Maintained by Express Network Private Ltd.